China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Genomic sequencing remains a relatively early stage market, and expanding sequencing indications, including the nascent liquid biopsy applications that would use its sequencers, create large growth ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Illumina is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 The company ...

and molecular techniques (DNA methylation quantification at candidate loci by pyrosequencing or at whole-genome level by bisulfite sequencing, measurements of expression of epigenome regulators) to ...

Objectives: The study aimed to investigate the clinical use of noninvasive prenatal ... sequencing depth. GC bias was eliminated by bioinformatic methods combined with local weighted polynomial ...

The costs of genomic sequencing have fallen very rapidly for the past decade and will continue to do so. As it becomes less ...

The provision will enable whole genome sequencing for neonatal and paediatric patients in intensive care units within 48 ...

Upper tract urothelial carcinoma (UTUC) is an aggressive disease that is challenging to biopsy and diagnose, frequently yielding nondiagnostic cytology and tissue specimens. Therefore, UTUC is often ...

In the first instalment of a series to mark the 10th anniversary of the Future Science Prize, Holly Chik and Shen Xinmei look ...